Exelixis Stock Price and Value Analysis

Exelixis (NasdaqGS:EXEL) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Exelixis to reach your target.

Target type

EXEL Free Cash Flow Trend

Free Cash Flow trendline for EXEL
Free Cash Flow trendline for Exelixis

Hmm, we can't give any reliable projection for Exelixis's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the EXEL Numbers

EXEL Price
(Exelixis stock price per share)
$70.70
[?] PE Ratio versus Sector 4% higher than other Healthcare stocks
[?] PE Ratio versus Industry 63% lower than other Biotechnology stocks
[?] Cash Yield -0.81%
[?] Free Cash Flow Jitter 91%

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-16.

The six months before that had 1 buy and 0 sales.

Recent Insider Activity

Open-market buys and sells reported by Exelixis's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2025-11-25 JOHNSON DAVID EDWARD Buy 27,532 $43.12
2024-05-30 JOHNSON DAVID EDWARD Buy 225,000 $20.76
2024-05-28 JOHNSON DAVID EDWARD Buy 200,000 $20.32
2024-02-21 JOHNSON DAVID EDWARD Buy 190,000 $20.70
2023-11-27 JOHNSON DAVID EDWARD Sell 120,409 $21.61
2023-11-27 JOHNSON DAVID EDWARD Buy 120,409 $21.61

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 25,593,708 shares shorted. With 209,127,097 shares available for purchase and an average trading volume over the past 10 trading days of 3,879,340, it would take at least 6.6 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Price Versus Our Estimated Value

Free cash flow was positive in 10 out of 17 reported years for Exelixis, using only its current SEC filer.

We do not estimate a fair value for Exelixis while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 91%.

We do not have a dividend yield for Exelixis.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

Its trailing P/E ratio is 4% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 63% below the average for stocks in the Biotechnology industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 939767.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Free cash flow was negative in 7 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in EXEL

Does Exelixis have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: EXEL

This example shows how we apply the Trendshare checklist to EXEL: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 70.70
    • Market cap: $17B
    • EPS: 3.34
  2. Step 2 — Valuation checks

    • P/E: 21.168
    • FCF yield: -0.8%
    • Date checked: Nov 11, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.